• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    1/27/23 4:31:03 PM ET
    $AKAN
    $CALA
    $CELZ
    $HSCS
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • Vaccitech (NASDAQ:VACC) shares rose 8.5% to $3.2 during Friday's after-market session. The company's market cap stands at $119.3 million.
    • Calithera Biosciences (NASDAQ:CALA) shares rose 7.34% to $0.39. The market value of their outstanding shares is at $1.8 million.
    • Ocuphire Pharma (NASDAQ:OCUP) shares increased by 6.45% to $3.63. The market value of their outstanding shares is at $75.5 million.
    • Creative Medical Tech (NASDAQ:CELZ) stock increased by 6.12% to $0.59. The company's market cap stands at $8.2 million.
    • Sharps Technology (NASDAQ:STSS) shares rose 5.88% to $1.44. The company's market cap stands at $13.5 million.
    • Summit Therapeutics (NASDAQ:SMMT) shares increased by 4.95% to $3.39. Trading volume for this security closed at 174.7K, accounting for 1.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $716.3 million.

    Losers

    • Akanda (NASDAQ:AKAN) stock declined by 9.9% to $0.31 during Friday's after-market session. Akanda's trading volume hit 12.9 million shares by close, accounting for 440.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $10.5 million.
    • Heart Test Laboratories (NASDAQ:HSCS) stock declined by 9.76% to $0.79. The market value of their outstanding shares is at $6.5 million.
    • Zynerba Pharmaceuticals (NASDAQ:ZYNE) shares declined by 6.48% to $0.62. The company's market cap stands at $29.1 million.
    • Quince Therapeutics (NASDAQ:QNCX) shares decreased by 5.56% to $1.02. Today's trading volume for this security ended up closing at 17.4 million shares, which is 7279.1 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $36.8 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares declined by 5.41% to $0.7. The market value of their outstanding shares is at $6.7 million.
    • NanoVibronix (NASDAQ:NAOV) shares fell 5.01% to $0.3. The company's market cap stands at $9.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $CALA
    $CELZ
    $HSCS

    CompanyDatePrice TargetRatingAnalyst
    Summit Therapeutics Inc.
    $SMMT
    3/16/2026$15.00Buy → Hold
    Jefferies
    Quince Therapeutics Inc.
    $QNCX
    1/30/2026Mkt Outperform → Mkt Perform
    Citizens JMP
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    9/4/2025$40.00Buy
    Guggenheim
    Summit Therapeutics Inc.
    $SMMT
    8/19/2025$21.00Neutral
    Piper Sandler
    Quince Therapeutics Inc.
    $QNCX
    8/5/2025$9.00Mkt Outperform
    Citizens JMP
    More analyst ratings

    $AKAN
    $CALA
    $CELZ
    $HSCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

    Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today reported financial results for its fiscal third quarter ended January 31, 2026 ("FQ3 2026") and provided a business update. Third Quarter and Recent Highlights During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administra

    3/16/26 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    First Towers & Fiber Corp. Owns the Largest Dark Fiber Network in Central Mexico

    Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, announced today plans to further expand the leasing of its approximately 700-kilometre dark fiber optic network located in Central Mexico. The network represents the largest dark fiber infrastructure in the region, serving several of Mexico's most active industrial corridors and fastest-growing state economies.The network was constructed following the execution of a 20-year long-term dark fiber lease agreement with Telefónica, the Spanish multinationa

    2/27/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Summit Therapeutics to Present at Upcoming Investor Conferences

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday, March 10, 2026 Investor meetings only Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026 Fireside chat 2:15pm ET The fireside chats will be available live on our website: www.

    2/26/26 6:45:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CALA
    $CELZ
    $HSCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wolf Lisa G

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    3/19/26 9:14:41 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Handley Michael K converted options into 8,824 shares (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    2/20/26 4:19:42 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Falconx Holdings Ltd sold $1,490,755 worth of shares (769,320 units at $1.94) and exercised 461,538 in-the-money shares at a strike of $0.00 (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:45:04 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $AKAN
    $CALA
    $CELZ
    $HSCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Summit Therapeutics downgraded by Jefferies with a new price target

    Jefferies downgraded Summit Therapeutics from Buy to Hold and set a new price target of $15.00

    3/16/26 8:36:55 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quince Therapeutics downgraded by Citizens JMP

    Citizens JMP downgraded Quince Therapeutics from Mkt Outperform to Mkt Perform

    1/30/26 6:43:10 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Summit Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Summit Therapeutics from Underweight to Equal Weight and set a new price target of $18.00

    12/17/25 8:48:06 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CALA
    $CELZ
    $HSCS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 9:06:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $499,983 worth of shares (26,680 units at $18.74) and was granted 14,247,597 shares, increasing direct ownership by 3% to 570,073,879 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 4:08:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CALA
    $CELZ
    $HSCS
    SEC Filings

    View All

    Amendment: SEC Form F-1/A filed by Akanda Corp.

    F-1/A - AKANDA CORP. (0001888014) (Filer)

    3/20/26 5:17:52 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Tivic Health Systems Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/20/26 5:15:08 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by Creative Medical Technology Holdings Inc.

    10-K - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    3/20/26 4:45:28 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $AKAN
    $CALA
    $CELZ
    $HSCS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for RYZUMVI issued to OCUPHIRE PHARMA INC

    Submission status for OCUPHIRE PHARMA INC's drug RYZUMVI (ORIG-1) with active ingredient PHENTOLAMINE has changed to 'Approval' on 09/25/2023. Application Category: NDA, Application Number: 217064, Application Classification: Type 3 - New Dosage Form

    9/26/23 12:02:02 PM ET
    $OCUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $CALA
    $CELZ
    $HSCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

    SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

    11/14/24 4:00:05 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Quince Therapeutics Inc.

    SC 13D - Quince Therapeutics, Inc. (0001662774) (Subject)

    11/13/24 9:17:26 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKAN
    $CALA
    $CELZ
    $HSCS
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an

    8/11/25 4:05:00 PM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $AKAN
    $CALA
    $CELZ
    $HSCS
    Financials

    Live finance-specific insights

    View All

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

    Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, phy

    2/17/26 5:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell

    11/6/25 9:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care